Loading patent…
AssigneesInstitut Pasteur de Lille, Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsLuis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
Estimating the term…
A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
A method of reducing or preventing the development of airway inflammation in a subject, the method comprising the step of administering to the respiratory tract of the subject an amount of a composition comprising a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject, wherein colonization of the respiratory tract of the subject results in reduction or prevention of the development of airway inflammation in the subject.
A composition comprising a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria capable of colonizing the respiratory tract of a subject and reducing or preventing the development of airway inflammation in the subject.
The BPZE1P strain deposited with the Collection Nationale de Cultures de Microorganismes under accession number CNCM-I-5150.
Dependencies are inferred from the claim text.